Literature DB >> 12439734

Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group.

D C Anderson1, B Gomez-Mancilla, B B Spear, D M Barnes, K Cheeseman, P M Shaw, J Friedman, A McCarthy, C Brazell, S C Ray, D McHale, L Hashimoto, R Sandbrink, M L Watson, R A Salerno, N Cohen, C E Lister.   

Abstract

Mesh：

Year:  2002        PMID： 12439734     DOI： 10.1038/sj.tpj.6500131

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN： 1470-269X            Impact factor:   3.550


× No keyword cloud information.
  5 in total

Review 1.  Incidental findings found in "healthy" volunteers during imaging performed for research: current legal and ethical implications.

Authors:  T C Booth; A Jackson; J M Wardlaw; S A Taylor; A D Waldman
Journal:  Br J Radiol       Date:  2010-03-24       Impact factor: 3.039

2.  Issues surrounding biospecimen collection and use in clinical trials.

Authors:  Allison R Baer; Mary Lou Smith; Deborah Collyar; Jeffrey Peppercorn
Journal:  J Oncol Pract       Date:  2010-07       Impact factor: 3.840

Review 3.  A review of consent practices and perspectives for pharmacogenetic testing.

Authors:  Susanne B Haga; Rachel Mills
Journal:  Pharmacogenomics       Date:  2016-08-17       Impact factor: 2.533

Review 4.  Within and beyond the communal turn to informed consent in industry-sponsored pharmacogenetics research: merits and challenges of community advisory boards.

Authors:  Hojjat Soofi; Evert van Leeuwen
Journal:  J Community Genet       Date:  2016-08-05

Review 5.  Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations.

Authors:  Katherine I Morley; Wayne D Hall
Journal:  J Mol Med (Berl)       Date:  2003-11-04       Impact factor: 4.599
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.